Preclinical antitumor activity of two novel taxanesROSE, William C; FAIRCHILD, Craig; LEE, Francis Y. F et al.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 2, pp 97-105, issn 0344-5704Article

Preclinical efficacy spectrum and pharmacokinetics of ixabepiloneLEE, Francis Y. F; SMYKLA, Richard; JOHNSTON, Kathy et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 2, pp 201-212, issn 0344-5704, 12 p.Article

The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsTOKARSKI, John S; NEWITT, John A; DIANLIN XIE et al.Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5790-5797, issn 0008-5472, 8 p.Article

Preclinical pharmacology of BMS-275183, an orally active taxaneROSE, William C; LONG, Byron H; FAIRCHILD, Craig R et al.Clinical cancer research. 2001, Vol 7, Num 7, pp 2016-2021, issn 1078-0432Article

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaPORKKA, Kimmo; KOSKENVESA, Perttu; ECCERSLEY, Lydia et al.Blood. 2008, Vol 112, Num 4, pp 1005-1012, issn 0006-4971, 8 p.Article

In vivo evaluation of Ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer modelsPETERSON, Jennifer K; TUCKER, Chandra; FAVOURS, Edward et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6950-6958, issn 1078-0432, 9 p., 1Article

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2.N-[5-[ [[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4piperidinecarboxamide (bms-387032), a highly efficacious and selective antitumor agentMISRA, Raj N; XIAO, Hai-Yun; LIGANG QIAN et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 7, pp 1719-1728, issn 0022-2623, 10 p.Article

Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2- thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activityHUNT, John T; DING, Charles Z; SOONG HOON KIM et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 20, pp 3587-3595, issn 0022-2623Article

Metabolism and Disposition of Dasatinib after Oral Administration to HumansCHRISTOPHER, Lisa J; DONGHUI CUI; GALBRAITH, Susan et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1357-1364, issn 0090-9556, 8 p.Article

BMS-247550 : A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacyLEE, Francis Y. F; BORZILLERI, Robert; FAIRCHILD, Craig R et al.Clinical cancer research. 2001, Vol 7, Num 5, pp 1429-1437, issn 1078-0432Article

Preclinical discovery of ixabepilone, a highly active antineoplastic agentLEE, Francis Y. F; BORZILLERI, Robert; FAIRCHILD, Craig R et al.Cancer chemotherapy and pharmacology. 2008, Vol 63, Num 1, pp 157-166, issn 0344-5704, 10 p.Article

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor modelsMANNE, Veeraswamy; LEE, Francis Y. F; TAI WAI WONG et al.Cancer research (Baltimore). 2004, Vol 64, Num 11, pp 3974-3980, issn 0008-5472, 7 p.Article

Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitorROSE, William C; LEE, Francis Y. F; FAIRCHILD, Craig R et al.Cancer research (Baltimore). 2001, Vol 61, Num 20, pp 7507-7517, issn 0008-5472Article